论文部分内容阅读
对本科住院治疗的初治急性作淋巴细胞白血病（ANLL）61例，分别给于DA、DAE方案化疗。结果：①初治ANLLDA方案的CR率64．3％，DAE方案CR率75．8％，两者CR率P＞0．05；②达CR时所需的疗程：DA方案1．7疗程，DAE方案1．4疗程；③两方案毒副反应大致相似、可以耐受。结论：DAE方案并不能提高CR率，但可能加快CR过程，且不增加毒副作用，可推广运用。
For the initial treatment of undergraduate hospitalized patients with acute lymphoblastic leukemia (ANLL), 61 patients were given DA, DAE chemotherapy. RESULTS: 1 The CR rate of the initially treated ANLLDA regimen was 64.3%, the CR rate of the DAE regimen was 75.8%, and the CR rate of the two regimens was P>0.05. 2 The course of treatment needed for achieving CR was 1.7 days of the DA regimen. DAE program 1.4 course of treatment; 3 Both programs are similar in toxicity and can be tolerated. Conclusion: The DAE program can not increase the CR rate, but it may speed up the CR process without increasing the side effects. It can be widely used.